The MET gene amplification is another frequent mechanism of acquired resistance and affects 5–20% EGFR-TKI treated NSCLC patients, irrespective of the T790M mutation status [167,168,169]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.